The latest price target for Bright Minds Biosciences (NASDAQ:DRUG) was reported by HC Wainwright & Co. on February 19, 2025. The analyst firm set a price target for $85.00 expecting DRUG to rise to within 12 months (a possible 140.86% upside). 5 analyst firms have reported ratings in the last year.

The latest analyst rating for Bright Minds Biosciences (NASDAQ:DRUG) was provided by HC Wainwright & Co., and Bright Minds Biosciences reiterated their buy rating.

There is no last upgrade for Bright Minds Biosciences

There is no last downgrade for Bright Minds Biosciences.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Bright Minds Biosciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Bright Minds Biosciences was filed on February 19, 2025 so you should expect the next rating to be made available sometime around February 19, 2026.

While ratings are subjective and will change, the latest Bright Minds Biosciences (DRUG) rating was a reiterated with a price target of $85.00 to $85.00. The current price Bright Minds Biosciences (DRUG) is trading at is $35.29, which is out of the analyst’s predicted range.